A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.
Novo Nordisk thus announces on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has suggested that Ozempic be approved in a new dose of its active ingredient of 2.0 mg. Ozempic, which is a GLP-1 analog, is used in the treatment of diabetes patients with type 2 diabetes, which is already approved in the doses of 0.5 mg and 1.0 mg.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Account Manager 
Consultant Manager 
Project Manager & Scrum Master 
Clinical Project Manager 
Analytical Senior Scientist 
Vice President, Test & Characterisation 
Quality System Manager 
Chemist for Incoming Materials in QC Department 
Director Global Engineering 
(Senior) Drug Substance Specialist 
IRT Manager, Clinical Drug Supply 
Key Account Manager, Europe and Asia 
Procurement Process Excellence Specialist 
Nordic Medical Affairs Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office